ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2008
Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 5 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Comparative safety and efficacy of brinzolamide/timolol and dorzolamide/timolol in the treatment of glaucoma patients: A systematic review and meta-analysis.European journal of ophthalmology · 2026Pooled it
- Latanoprost/timolol fixed-dose combination: two decades of efficacy and safety in glaucoma management.BMC ophthalmology · 2026Pooled it
- Cannabis use and the risk of primary open-angle glaucoma: a Mendelian randomization study.Scientific reports · 2023Pooled it
- Eliciting preferences in glaucoma management-a systematic review of stated-preference studies.Eye (London, England) · 2023Pooled it
- Topical medication instillation techniques for glaucoma.The Cochrane database of systematic reviews · 2017Pooled it
- From design to Deployment: The innovative role of nanomicelles in targeted ophthalmic therapeutics.Materials today. Bio · 2025Review
- Long-term effectiveness of the trabecular micro-bypass (iStent): 3-year real world data in glaucoma and ocular hypertension.International ophthalmology · 2025Article
- Emerging trends in long-acting sustained drug delivery for glaucoma management.Drug delivery and translational research · 2025Review
- Exploring the effect of SGLT2 inhibitors on the risk of primary open-angle glaucoma using Mendelian randomization analysis.Scientific reports · 2025Article
- Improvement of Presbyopia, Dry Eye, Intraocular Pressure, and Near Vision Through Cassiae Tea Consumption.Medicina (Kaunas, Lithuania) · 2024Article
- Beyond the Dusty Fog: Local Eye Drop Therapy and Potentially New Treatment Alternatives in Pseudoexfoliative Glaucoma.Current medicinal chemistry · 2024Review
- Association of topical glaucoma medications with lacrimal drainage obstruction and eyelid malposition.Eye (London, England) · 2023Article
- Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia.Eye (London, England) · 2023Article
- Caveolin-1 in vascular health and glaucoma: A critical vascular regulator and potential therapeutic target.Frontiers in medicine · 2023Review
- Patients' Satisfaction with Topical Anti-Glaucoma Medications and Associated Factors at Gondar University Tertiary Eye Care and Training Center, Northwest Ethiopia, 2021.Clinical optometry · 2023Article
- Patient Medication Preferences for Managing Dry Eye Disease: The Importance of Medication Side Effects.The patient · 2022Article
- The development of a glaucoma-specific health-related quality of life item bank supporting a novel computerized adaptive testing system in Asia.Journal of patient-reported outcomes · 2022Article
- Sustained-release drug delivery systems for the treatment of glaucoma.International journal of ophthalmology · 2021Review
- Adreno-melatonin receptor complexes control ion homeostasis and intraocular pressure - their disruption contributes to hypertensive glaucoma.British journal of pharmacology · 2020Article
- Initial Glaucoma Medication in the Hypertensive Phase Following Ahmed Valve Implantation: A Comparison of Results Achieved Using Aqueous Suppressants and Prostaglandin Analogs.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo compare the tolerability of commonly prescribed topical glaucoma medications by determining frequency and bother of side effects, patient satisfaction with their medication, and the chance of discontinuation of eye drops.
methodsThe tolerability of topical glaucoma medication was studied in glaucoma patients from nine hospitals. The frequency and severity of side effects was investigated together with patient satisfaction with the medication and the probability to change medication due to reported side effects. To register side effects of topical glaucoma medication, patients were requested to fill in a questionnaire based on "the Comparison of Ophthalmic Medications for Tolerability" (COMTOL) questionnaire supplemented with items based on the most frequently observed and severe side effects.
resultsThe number of patients responding was 3,333 (87%). Most patients (79%) were satisfied with their eye medication. The median score for ocular side effects was 58 on a scale ranging from 0 to 320. The probability that medication would be changed by the ophthalmologist at the next visit due to reported side effects occurring since the patients' last or last but one visit to the ophthalmologist was 9%. The most frequently prescribed drugs were timolol, latanoprost, and the fixed combinations of dorzolamide/timolol (Cosopt) and latanoprost/timolol (Xalcom). Only small differences in tolerability were found between these drugs.
conclusionsThe tolerability of timolol, latanoprost, and the fixed combinations of latanoprost/timolol (Xalcom) and dorzolamide/timolol (Cosopt) seem to be comparable. Patients are satisfied with their glaucoma medication and have a low chance of discontinuation of eye drops due to side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.